Synthetic inhibitor leads of human tropomyosin receptor kinase A ( h TrkA).
Subramanian, G., Vairagoundar, R., Bowen, S.J., Roush, N., Zachary, T., Javens, C., Williams, T., Janssen, A., Gonzales, A.(2020) RSC Med Chem 11: 370-377
- PubMed: 33479642 
- DOI: https://doi.org/10.1039/c9md00554d
- Primary Citation of Related Structures:  
6PMA, 6PMB, 6PMC, 6PME - PubMed Abstract: 
In silico virtual screening followed by in vitro biochemical, biophysical, and cellular screening resulted in the identification of distinctly different h TrkA kinase domain inhibitor scaffolds. X-ray structural analysis of representative inhibitors bound to h TrkA kinase domain defined the binding mode and rationalized the mechanism of action. Preliminary assessment of the sub-type selectivity against the closest h TrkB isoform, and early ADME guided the progression of select inhibitor leads in the screening cascade. The possibility of the actives sustaining to known h TrkA resistance mutations assessed in silico offers initial guidance into the required multiparametric lead optimization to arrive at a clinical candidate.
Organizational Affiliation: 
Veterinary Medicine Research & Development , Zoetis , 333 Portage Street , Kalamazoo , MI 49007 , USA . Email: govindan.subramanian@zoetis.com.